Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-03-20
2011-12-06
Saeed, Kamal (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S217080, C514S235200, C514S339000, C514S414000, C540S602000, C544S143000, C546S277400, C548S466000
Reexamination Certificate
active
08071584
ABSTRACT:
The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I):wherein R1, R2, R3, R4, and m are as defined herein.The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, rhinitis, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
REFERENCES:
patent: 4775761 (1988-10-01), Strupczewski
patent: 5026856 (1991-06-01), Yatsunami et al.
patent: 5256673 (1993-10-01), Böttcher et al.
patent: 6245799 (2001-06-01), Asselin et al.
patent: 6358944 (2002-03-01), Fritz et al.
patent: 6589954 (2003-07-01), Mavunkel et al.
patent: 6919335 (2005-07-01), Iwanowicz et al.
patent: 2002/0147189 (2002-10-01), Cai et al.
patent: 2002/0161004 (2002-10-01), Browner et al.
patent: 2003/0022898 (2003-01-01), Burke et al.
patent: 2006/0281836 (2006-12-01), Kerns et al.
patent: 2007/0254873 (2007-11-01), Kerns et al.
patent: 2007/0281933 (2007-12-01), Kerns et al.
patent: 2008/0269291 (2008-10-01), Kerns et al.
patent: 2008/0293802 (2008-11-01), Kerns et al.
patent: 2009/0143372 (2009-06-01), Kerns et al.
patent: 2010/0130468 (2010-05-01), Busch-Petersen et al.
patent: 3342632 (1985-06-01), None
patent: 19500689 (1996-07-01), None
patent: 19807993 (1999-09-01), None
patent: 19928424 (2000-12-01), None
patent: 10112151 (2002-09-01), None
patent: 10259244 (2004-07-01), None
patent: 279263 (1993-08-01), None
patent: 610134 (1994-08-01), None
patent: 416609 (1997-01-01), None
patent: 0812826 (1997-12-01), None
patent: 1077213 (2001-02-01), None
patent: 1134221 (2001-09-01), None
patent: 1209158 (2002-05-01), None
patent: WO94/21627 (1994-09-01), None
patent: WO94/21630 (1994-09-01), None
patent: WO98/06715 (1998-02-01), None
patent: WO98/28292 (1998-07-01), None
patent: WO99/43652 (1999-02-01), None
patent: WO99/17773 (1999-04-01), None
patent: WO0100610 (2001-01-01), None
patent: WO01/34598 (2001-05-01), None
patent: WO0130774 (2001-05-01), None
patent: WO0158890 (2001-08-01), None
patent: WO0168648 (2001-09-01), None
patent: WO01/83472 (2001-11-01), None
patent: WO01/87298 (2001-11-01), None
patent: WO0198290 (2001-12-01), None
patent: WO02/14317 (2002-02-01), None
patent: WO02/16353 (2002-02-01), None
patent: WO02/24693 (2002-03-01), None
patent: WO0224679 (2002-03-01), None
patent: WO0228860 (2002-03-01), None
patent: WO0230353 (2002-04-01), None
patent: WO02230423 (2002-04-01), None
patent: WO0241843 (2002-05-01), None
patent: WO0244153 (2002-06-01), None
patent: WO0246171 (2002-06-01), None
patent: WO02/051837 (2002-07-01), None
patent: WO02060386 (2002-08-01), None
patent: WO02094265 (2002-11-01), None
patent: WO02094322 (2002-11-01), None
patent: WO02094813 (2002-11-01), None
patent: WO03007076 (2003-01-01), None
patent: WO03010158 (2003-02-01), None
patent: WO03010163 (2003-02-01), None
patent: WO03022898 (2003-03-01), None
patent: WO03024935 (2003-03-01), None
patent: WO03024936 (2003-03-01), None
patent: WO03027075 (2003-04-01), None
patent: WO03037886 (2003-05-01), None
patent: WO03065625 (2003-05-01), None
patent: WO03/087087 (2003-10-01), None
patent: WO03084959 (2003-10-01), None
patent: WO03095430 (2003-11-01), None
patent: WO03/101987 (2003-12-01), None
patent: WO03103661 (2003-12-01), None
patent: WO2004/019935 (2004-03-01), None
patent: WO2004/024730 (2004-03-01), None
patent: WO2004/024732 (2004-03-01), None
patent: WO2004/024736 (2004-03-01), None
patent: WO2004022553 (2004-03-01), None
patent: WO2004075846 (2004-09-01), None
patent: WO2004089913 (2004-10-01), None
patent: WO2004106293 (2004-12-01), None
patent: WO2005012283 (2005-02-01), None
patent: WO2005035537 (2005-04-01), None
patent: WO2005067923 (2005-07-01), None
patent: WO2006/002434 (2006-01-01), None
patent: WO 2006/034317 (2006-03-01), None
patent: WO2006/106326 (2006-10-01), None
patent: WO2007/005534 (2007-01-01), None
Aupperle et al., “NF-κB Regulation by IκB Kinase in Primary Fibroblast-Like Synoviocytes”J. Immunology(1999) 163:427-433.
Aupperle et al., “Nf-κB Regulation by lκB Kinase-2 in Rheumatoid Arthritis Synoviocytes”J. Immunology(2001) 166:31496-31501.
Breton et al., “The Natural Product Hymenialdisine Inhibits Interleukin-8 Production in U937 Cells by Inhibition of Nuclear Factor-κB”JPET(1997) 282(1):459-466.
Burke et al., “BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice”J. Biol Chem. (2003) 278:1450-1456.
Guttridge et al., “Nκ-B-Induced Loss ofMyoDMessenger RNA: Possible Role in Muscle Decay and Cachexia ” Science (2000) 289:2363-2365.
Murata et al., “Discovery of novel and selective IKK-β serine-threonine protein kinase inhibitors. Part 1.”Bioorg. Med. Chem. Letter(2003) 13:913-198.
Murata et al., “Synthesis and structure—activity relationships of novel IKK-β inhibitors. Part 2: Improvement of in vitro activity”Bioorg. Med. Chem. Letter(2004) 14(15):4013-4017 and “Synthesis and structure—activity relationships of novel IKK-β inhibitors. Part 3: Orally active anti-inflammatory agents,”Bioorg. Med. Chem. Letter(2004) 14(15):4019-4022.
Peet et al., “IκB Kinases α and β Show a Random Sequential Kinetic Mechanism and Are Inhibited by Staurosporine and Quercetin”J. Biol. Chem. (1999) 274:32655-32661.
Pierce, et al., “Novel Inhibitors of Cytokine-induced IκBκ Phosphorylation and Endothelial Cell Adhesion Molecule Expression Show Anti-inflammatory Effects in Vivo”J. Biol. Chem. (1997) 272:21096-21103.
Roshak, et al., “Inhibition of NFκB-Mediated Interleukin-1β-Stimulated Prostaglandin E2Formation by the Marine Natural Product Hymenialdisine”JPET(1997) 283(2):955-961.
Roshak, et al., “Manipulation of Distinct NFκB Proteins Alters Interleukin-lβ-induced Human Rheumatoid Synovial Fibroblast Prostaglandin E2Formation”J. Biol. Chem. (1996) 271:31496-31501.
Sullivan et al., “2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3',5'-bis(trifluoromethyl)phenyl)-carboxamide: A Potent Inhibitor of NF-κB- and AP-1-Mediated Gene Expression Identified Using Solution-Phase Combinatorial Chemistry”J. Med. Chem. (1998) 41:413-419.
Tak et al., “Inhibitor of nuclear factor κB kinase β is a key regulator of synovial inflammation”Arthritis and Rheumatism(2001) 44(8):1897-1907.
Wahl et al., “Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B”J. Clin. Invest.(1998) 101(5):1163-1174.
Wisniewski et al., “Assay for IκB Kinases Using an in Vivo Biotinylated IκB Protein Substrate”Analytical Biochem. (1999) 274:220-228.
U.S. Appl. No. 12/093,750, filed May 15, 2008, Kerns et al.
U.S. Appl. No. 12/096,397, filed Jun. 6, 2008, Kerns et al.
U.S. Appl. No. 12/532,773, filed Sep. 23, 2009, Busch-Petersen et al.
U.S. Appl. No. 10/597,154, filed Jul. 13, 2006, Baldwin et al.
U.S. Appl. No. 11/570,060, filed Dec. 5, 2006, Jeffrey K. Kerns.
U.S. Appl. No. 11/575,416, filed Mar. 16, 2007, Kerns et al.
C. G. Wermuth.The Practice of Medicinal Chemistry, Academic Press, pp. 203-214 (1996).
Restriction Requirement dated May 20, 2009 in U.S. Appl. No. 10/597,154.
Official Action dated Oct. 27, 2009 in U.S. Appl. No. 10/597,154.
Final Action dated Jul. 15, 2010 in U.S. Appl. No. 10/597,154.
Restriction Requirement dated Dec. 15, 2009 in U.S. Appl. No. 11/570,060.
Official Action dat
Boehm Jeffrey Charles
Busch-Petersen Jakob
Fu Wei
Jin Qi
Kerns Jeffrey K.
Bianchi Kristin
Furman Theodore R.
GlaxoSmithKline LLC
Saeed Kamal
Stein Nora L.
LandOfFree
Indole carboxamides as IKK2 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indole carboxamides as IKK2 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indole carboxamides as IKK2 inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4312718